Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Uniqure N.V. (QURE)

Uniqure N.V. (QURE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 911,035
  • Shares Outstanding, K 46,648
  • Annual Sales, $ 524,000 K
  • Annual Income, $ 329,590 K
  • 60-Month Beta 1.01
  • Price/Sales 1.70
  • Price/Cash Flow 2.56
  • Price/Book 1.79
Trade QURE with:

Options Overview Details

View History
  • Implied Volatility 72.46% ( -10.59%)
  • Historical Volatility 105.09%
  • IV Percentile 13%
  • IV Rank 22.03%
  • IV High 106.47% on 11/26/21
  • IV Low 62.85% on 08/13/21
  • Put/Call Vol Ratio 0.29
  • Today's Volume 132
  • Volume Avg (30-Day) 393
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 27,547
  • Open Int (30-Day) 26,194

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -1.11
  • Number of Estimates 8
  • High Estimate -0.59
  • Low Estimate -1.31
  • Prior Year -0.79
  • Growth Rate Est. (year over year) -40.51%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.75 +16.60%
on 08/08/22
25.81 -24.33%
on 07/29/22
-3.24 (-14.23%)
since 07/08/22
3-Month
12.52 +55.99%
on 05/12/22
25.81 -24.33%
on 07/29/22
+5.62 (+40.40%)
since 05/10/22
52-Week
12.52 +55.99%
on 05/12/22
38.80 -49.66%
on 09/21/21
-10.09 (-34.06%)
since 08/10/21

Most Recent Stories

More News
Why uniQure Stock Is Crashing Today

The company is temporarily delaying higher-dose procedures of experimental gene therapy AMT-130.

QURE : 19.53 (+2.68%)
UniQure (QURE) Reports Q2 Loss, Lags Revenue Estimates

uniQure (QURE) delivered earnings and revenue surprises of 12.50% and 97.47%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

QURE : 19.53 (+2.68%)
PHAS : 1.1400 (-10.94%)
uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress

~ Announced 12-month data on the lower-dose cohort of AMT-130 in Huntington’s disease showed the investigative gene therapy was generally well tolerated at...

QURE : 19.53 (+2.68%)
Fulgent Genetics Welcomes Dr. Michael Nohaile and Dr. Leonard Post to Board of Directors

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent” or the “company”) today announced the addition of two therapeutic industry veterans to its board of directors. Dr. Michael...

FLGT : 52.21 (+4.21%)
QURE : 19.53 (+2.68%)
uniQure (QURE) Up on Safety Data From Huntington's Disease Study

uniQure (QURE) posts safety and biomarker data from the 10 patients enrolled in the lower-dose cohort of its ongoing phase I/II study evaluating AMT-130 for treating Huntington's disease.

QURE : 19.53 (+2.68%)
AGLE : 0.4623 (+12.07%)
LPTX : 1.1700 (+7.34%)
DTIL : 1.6500 (+7.84%)
uniQure (QURE) Moves 27% Higher: Will This Strength Last?

uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

QURE : 19.53 (+2.68%)
TELA : 8.55 (-1.38%)
Why uniQure's Stock Price Jumped Today

It just reported a packet of promising safety data for its flagship pipeline program.

QURE : 19.53 (+2.68%)
uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean...

QURE : 19.53 (+2.68%)
CORRECTION -- uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 22, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by uniQure...

QURE : 19.53 (+2.68%)
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 22, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing...

QURE : 19.53 (+2.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus...

See More

Key Turning Points

3rd Resistance Point 20.81
2nd Resistance Point 20.26
1st Resistance Point 19.90
Last Price 19.53
1st Support Level 18.98
2nd Support Level 18.43
3rd Support Level 18.07

See More

52-Week High 38.80
Fibonacci 61.8% 28.76
Fibonacci 50% 25.66
Fibonacci 38.2% 22.56
Last Price 19.53
52-Week Low 12.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar